MLICM
DAWN

Metropolitan Life Insurance Company (MetLife)’s Day One Biopharmaceuticals DAWN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,691
Closed -$61K – 567
2024
Q1 		$61K Hold
3,691
– – ﹤0.01% 1307
2023
Q4 		$53.9K Hold
3,691
– – ﹤0.01% 1408
2023
Q3 		$45.3K Buy
3,691
+955
+35% +$12.5K ﹤0.01% 1458
2023
Q2 		$32.7K Buy
2,736
+1,192
+77% +$15.6K ﹤0.01% 1671
2023
Q1 		$20.6K Sell
1,544
-281
-15% -$5.49K ﹤0.01% 1874
2022
Q4 		$39.3K Hold
1,825
– – ﹤0.01% 1615
2022
Q3 		$36.6K Hold
1,825
– – ﹤0.01% 1675
2022
Q2 		$32.7K Hold
1,825
– – ﹤0.01% 1764
2022
Q1 		$18.1K Buy
+1,825
New +$24.1K ﹤0.01% 2137
2021
Q4 		– Sell
-3,636
Closed -$86.3K – 2795
2021
Q3 		$86.3K Buy
+3,636
New +$87.1K ﹤0.01% 2605

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DAWN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 3,691 shares — an estimated $61K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DAWN in Q3 2021 and held it in 10 quarters. The position peaked at $86.3K in Q3 2021. 156 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,691 Day One Biopharmaceuticals shares in Q2 2024, an estimated $61K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 10 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Day One Biopharmaceuticals position peaked at $86.3K in Q3 2021.
  • 156 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.